The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 32, No. 12, pp. 1353-1361. DOI 10.1345/aph.18166
© 1998 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Klepser, M.
Right arrow Articles by Pfaller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klepser, M.
Right arrow Articles by Pfaller, M.


Research Articles

Therapy of Candida infections: susceptibility testing, resistance, and therapeutic options

ME Klepser, RE Lewis, and MA Pfaller

OBJECTIVE: Review the epidemiology of fungal infections, approved susceptibility testing methods, the scope of antifungal resistance, and advances in the treatment of fungal infections. DATA SOURCES: MEDLINE databases (from 1966 to March 1998) were searched for literature pertaining to the epidemiology and management of fungal infections. STUDY SELECTION AND DATA EXTRACTION: Articles were selected to assist in providing the reader an understanding of the epidemiology and management of fungal infections. DATA SYNTHESIS: Fungi have emerged as an important class of pathogens. Even though fungi rank as the fourth most commonly encountered nosocomial bloodstream pathogen, and are associated with the highest mortality of commonly encountered pathogens, only within the past year have methods for conducting and guidelines for interpreting in vitro susceptibility tests been approved. Under the guidance of these standards, we have begun to understand important issues regarding fungi such as the scope and mechanisms of antifungal resistance. Although there has not been a significant addition to our antifungal armamentarium since 1992, advances in antifungal therapy have been realized with the reformulation of available agents and the delineation of the pharmacodynamic characteristics of several antifungals. Additionally, several new agents, including a new class of antifungals, probably will enter into clinical use within the next 5 years. CONCLUSIONS: We have entered an era in which our understanding of fungi is increasing tremendously. Clinicians need to familiarize themselves with the current concepts surrounding the management of fungal infections in order to provide optimal care for their patients.


This article has been cited by other articles:


Home page
Infect. Immun.Home page
J. M. Rauceo, N. K. Gaur, K.-G. Lee, J. E. Edwards, S. A. Klotz, and P. N. Lipke
Global Cell Surface Conformational Shift Mediated by a Candida albicans Adhesin
Infect. Immun., September 1, 2004; 72(9): 4948 - 4955.
[Abstract] [Full Text] [PDF]


Home page
MicrobiologyHome page
P. K. Mukherjee, K. R. Seshan, S. D. Leidich, J. Chandra, G. T. Cole, and M. A. Ghannoum
Reintroduction of the PLB1 gene into Candida albicans restores virulence in vivo
Microbiology, September 1, 2001; 147(9): 2585 - 2597.
[Abstract] [Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1998 by Harvey Whitney Books Company.